LIN9

Summary

LIN9 (lin-9 DREAM MuvB core complex component, HGNC:30830) is a protein-coding gene on chromosome 1q42.12, encoding Protein lin-9 homolog (Q5TKA1). Acts as a tumor suppressor.

This gene encodes a tumor suppressor protein that inhibits DNA synthesis and oncogenic transformation through association with the retinoblastoma 1 protein. The encoded protein also interacts with a complex of other cell cycle regulators to repress cell cycle-dependent gene expression in non-dividing cells. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 286826 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 61 total
• MANE Select transcript: NM_001366245

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30830
Approved symbol	LIN9
Name	lin-9 DREAM MuvB core complex component
Location	1q42.12
Locus type	gene with protein product
Status	Approved
Aliases	TGS
Ensembl gene	ENSG00000183814
Ensembl biotype	protein_coding
OMIM	609375
Entrez	286826

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 12 protein_coding

ENST00000328205, ENST00000359525, ENST00000366808, ENST00000460719, ENST00000481685, ENST00000681046, ENST00000899464, ENST00000899465, ENST00000899466, ENST00000899467, ENST00000918994, ENST00000918995

RefSeq mRNA: 9 — MANE Select: NM_001366245 NM_001270409, NM_001270410, NM_001366237, NM_001366238, NM_001366239, NM_001366240, NM_001366241, NM_001366245, NM_173083

CCDS: CCDS1553, CCDS91164, CCDS91165

Canonical transcript exons

ENST00000681046 — 15 exons

Exon	Start	End
ENSE00001292598	226277775	226277932
ENSE00001293826	226266213	226266332
ENSE00001300920	226295842	226295946
ENSE00001306222	226250839	226250919
ENSE00001312187	226286333	226286458
ENSE00001313449	226267957	226268090
ENSE00001321890	226287664	226287797
ENSE00001324549	226265533	226265634
ENSE00001337987	226233096	226233193
ENSE00001337989	226233344	226233523
ENSE00001337990	226238971	226239096
ENSE00001442658	226231157	226232606
ENSE00003498432	226301173	226301205
ENSE00003593168	226297719	226297813
ENSE00003912496	226309109	226309164

Expression profiles

Bgee: expression breadth ubiquitous, 185 present calls, max score 86.67.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.5988 / max 149.6492, expressed in 1348 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
17748	5.5462	1338
17750	0.0526	13

Top tissues by expression

231 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	86.67	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.34	gold quality
ganglionic eminence	UBERON:0004023	84.35	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.77	gold quality
heart left ventricle	UBERON:0002084	79.42	gold quality
cardiac ventricle	UBERON:0002082	79.24	gold quality
secondary oocyte	CL:0000655	79.07	silver quality
heart right ventricle	UBERON:0002080	78.28	silver quality
oocyte	CL:0000023	77.32	gold quality
heart	UBERON:0000948	75.96	gold quality
apex of heart	UBERON:0002098	75.71	gold quality
cortical plate	UBERON:0005343	75.66	gold quality
calcaneal tendon	UBERON:0003701	75.35	gold quality
rectum	UBERON:0001052	73.70	gold quality
right atrium auricular region	UBERON:0006631	73.02	gold quality
smooth muscle tissue	UBERON:0001135	73.00	gold quality
cardiac atrium	UBERON:0002081	72.01	gold quality
stromal cell of endometrium	CL:0002255	71.17	gold quality
testis	UBERON:0000473	70.36	gold quality
muscle of leg	UBERON:0001383	70.22	gold quality
islet of Langerhans	UBERON:0000006	70.08	gold quality
gastrocnemius	UBERON:0001388	69.87	gold quality
vermiform appendix	UBERON:0001154	69.77	gold quality
bone marrow cell	CL:0002092	69.72	silver quality
right testis	UBERON:0004534	69.65	gold quality
lymph node	UBERON:0000029	69.39	gold quality
ovary	UBERON:0000992	69.04	gold quality
left testis	UBERON:0004533	68.86	gold quality
leukocyte	CL:0000738	68.62	gold quality
esophagus mucosa	UBERON:0002469	68.53	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.95

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

100 targeting LIN9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-340-5P	100.00	72.50	4437
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3065-5P	99.97	71.56	3281

Literature-anchored findings (GeneRIF, showing 12)

• Human Lin-9 has tumor-suppressing activities and the ability of hLin-9 to inhibit transformation is mediated through its association with pRB. (PMID:15538385)
• Mutation of BARA/LIN-9 restores the expression of E2F target genes. (PMID:16730350)
• Mip/LIN-9 is required for the expression of B-Myb, and both proteins collaborate in the control of the cell cycle progression via the regulation of S phase and cyclin A, cyclin B, and CDK1 (PMID:17098733)
• human LIN-9, together with B-MYB, has a critical role in the activation of genes that are essential for progression into mitosis (PMID:17159899)
• The repressor complex that Mip/LIN-9 forms with p107 takes functional precedence over the transcriptional activation linked to the Mip/LIN-9 and B-Myb interaction. (PMID:17563750)
• inactivation of LIN9, a subunit of DREAM, results in premature senescence, which can be overcome by the SV40 large T (LT) antigen (PMID:21860417)
• Study links hTRM9L and tRNA modifications to inhibition of tumour growth via LIN9 and HIF1-alpha-dependent mechanisms. (PMID:23381944)
• Results show that E7 interacts with the B-Myb, FoxM1 and LIN9 components of this activator complex, leading to cooperative transcriptional activation of mitotic genes in primary cells and E7 recruitment to the corresponding promoters. (PMID:24141769)
• LIN-9 phosphorylation on threonine-96 is required for transcriptional activation of LIN-9 target genes and promotes cell cycle progression. (PMID:24475316)
• The MuvB multiprotein complex, together with B-MYB and FOXM1 (MMB-FOXM1) regulate the expression of mitotic kinesins in breast cancer cells. (PMID:28061449)
• High LIN9 expression is associated with Triple-negative breast cancers. (PMID:28807940)
• LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance. (PMID:32054769)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	lin9	ENSDARG00000028475
mus_musculus	Lin9	ENSMUSG00000058729
rattus_norvegicus	Lin9	ENSRNOG00000023304
drosophila_melanogaster	aly	FBGN0004372
drosophila_melanogaster	mip130	FBGN0023509
caenorhabditis_elegans		WBGENE00002998

Protein

Protein identifiers

Protein lin-9 homolog — Q5TKA1 (reviewed: Q5TKA1)

Alternative names: Beta subunit-associated regulator of apoptosis, TUDOR gene similar protein, Type I interferon receptor beta chain-associated protein, pRB-associated protein

All UniProt accessions (5): Q5TKA1, B1B047, C9J5J4, H0Y322, H7C4T7

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a tumor suppressor. Inhibits DNA synthesis. Its ability to inhibit oncogenic transformation is mediated through its association with RB1. Plays a role in the expression of genes required for the G1/S transition.

Subunit / interactions. Component of the DREAM complex (also named LINC complex) at least composed of E2F4, E2F5, LIN9, LIN37, LIN52, LIN54, MYBL1, MYBL2, RBL1, RBL2, RBBP4, TFDP1 and TFDP2. The complex exists in quiescent cells where it represses cell cycle-dependent genes. It dissociates in S phase when LIN9, LIN37, LIN52 and LIN54 form a subcomplex that binds to MYBL2. Interacts with RB1.

Subcellular location. Nucleus. Nucleoplasm.

Tissue specificity. Expressed in thymus and testis.

Similarity. Belongs to the lin-9 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q5TKA1-1	1, Lin9-L, Long form	yes
Q5TKA1-2	2
Q5TKA1-3	3, Lin9-S, Short form

RefSeq proteins (9): NP_001257338, NP_001257339, NP_001353166, NP_001353167, NP_001353168, NP_001353169, NP_001353170, NP_001353174, NP_775106 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010561	LIN-9/ALY1	Family
IPR033471	DIRP	Domain
IPR045831	LIN9_C	Domain

Pfam: PF06584, PF19438

UniProt features (36 total): helix 10, modified residue 7, strand 7, turn 3, splice variant 2, sequence conflict 2, initiator methionine 1, chain 1, cross-link 1, region of interest 1, coiled-coil region 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
6C48	X-RAY DIFFRACTION	2.32
7N40	X-RAY DIFFRACTION	2.55
7R1D	ELECTRON MICROSCOPY	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5TKA1-F1	71.21	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 321, 21, 2, 65, 95, 96, 304, 309

Function

Pathways and Gene Ontology

Reactome pathways

14 pathways

ID	Pathway
R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex
R-HSA-1362300	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
R-HSA-1538133	G0 and Early G1
R-HSA-156711	Polo-like kinase mediated events
R-HSA-69202	Cyclin E associated events during G1/S transition
R-HSA-69205	G1/S-Specific Transcription
R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry
R-HSA-1640170	Cell Cycle
R-HSA-453274	Mitotic G2-G2/M phases
R-HSA-453279	Mitotic G1 phase and G1/S transition
R-HSA-69206	G1/S Transition
R-HSA-69242	S Phase
R-HSA-69275	G2/M Transition
R-HSA-69278	Cell Cycle, Mitotic

MSigDB gene sets: 196 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, TAATAAT_MIR126, REACTOME_G1_S_SPECIFIC_TRANSCRIPTION, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, TATTATA_MIR374, LE_EGR2_TARGETS_UP, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_DNA_BIOSYNTHETIC_PROCESS, DODD_NASOPHARYNGEAL_CARCINOMA_UP, FISCHER_DREAM_TARGETS, BERENJENO_TRANSFORMED_BY_RHOA_UP, TTTGCAC_MIR19A_MIR19B, DURCHDEWALD_SKIN_CARCINOGENESIS_DN, GOCC_RNA_POLYMERASE_II_TRANSCRIPTION_REGULATOR_COMPLEX

GO Biological Process (4): DNA-templated transcription (GO:0006351), regulation of transcription by RNA polymerase II (GO:0006357), regulation of cell cycle (GO:0051726), DNA biosynthetic process (GO:0071897)

GO Molecular Function (2): DNA binding (GO:0003677), protein binding (GO:0005515)

GO Cellular Component (3): nucleoplasm (GO:0005654), transcription repressor complex (GO:0017053), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Cell Cycle, Mitotic	3
G0 and Early G1	2
Mitotic G1 phase and G1/S transition	2
G1/S Transition	2
G2/M Transition	1
S Phase	1
Mitotic G2-G2/M phases	1
Cell Cycle	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
gene expression	1
RNA biosynthetic process	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
cell cycle	1
regulation of cellular process	1
DNA metabolic process	1
nucleic acid biosynthetic process	1
nucleic acid binding	1
binding	1
nuclear lumen	1
cellular anatomical structure	1
transcription regulator complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

944 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LIN9	LIN37	Q96GY3	999
LIN9	RBBP4	P31149	999
LIN9	LIN54	Q6MZP7	999
LIN9	LIN52	Q52LA3	998
LIN9	MYBL2	P10244	994
LIN9	E2F4	Q16254	939
LIN9	RBL2	Q08999	897
LIN9	FOXM1	Q08050	753
LIN9	RB1	P06400	740
LIN9	E2F5	Q15329	701
LIN9	MYBL1	P10243	679
LIN9	MSI1	O43347	665
LIN9	DPP6	P42658	638
LIN9	RBBP7	Q16576	625
LIN9	E2F1	Q01094	608

IntAct

81 interactions, top by confidence:

A	B	Type	Score
CDK2	CCNE2	psi-mi:“MI:0914”(association)	0.940
RBBP7	CDK2AP1	psi-mi:“MI:0914”(association)	0.840
RBBP4	CDK2AP1	psi-mi:“MI:0914”(association)	0.790
LIN37	RBL2	psi-mi:“MI:0914”(association)	0.770
LIN37	MYBL2	psi-mi:“MI:0914”(association)	0.730
LIN9	MYBL2	psi-mi:“MI:0914”(association)	0.720
LIN9	MYBL2	psi-mi:“MI:0915”(physical association)	0.720
MYBL2	LIN9	psi-mi:“MI:0915”(physical association)	0.720
LIN9	RBL2	psi-mi:“MI:0914”(association)	0.700
LIN9	RBL2	psi-mi:“MI:0915”(physical association)	0.700
RBL2	LIN9	psi-mi:“MI:0914”(association)	0.700
E2F4	LIN9	psi-mi:“MI:0915”(physical association)	0.670
LIN54	RBL2	psi-mi:“MI:0914”(association)	0.620
TCF19	E2F6	psi-mi:“MI:0914”(association)	0.620
LIN54	MYBL2	psi-mi:“MI:0914”(association)	0.560
RBL2	LIN52	psi-mi:“MI:0914”(association)	0.560

BioGRID (208): LIN9 (Affinity Capture-RNA), LIN9 (Affinity Capture-RNA), LIN9 (Affinity Capture-RNA), LIN9 (Affinity Capture-MS), LIN9 (Affinity Capture-MS), LIN9 (Affinity Capture-MS), LIN9 (Proximity Label-MS), LIN9 (Affinity Capture-MS), LIN9 (Affinity Capture-MS), LIN9 (Affinity Capture-MS), MYBL2 (Affinity Capture-Western), LIN9 (Affinity Capture-MS), LIN9 (Affinity Capture-MS), MYBL2 (Affinity Capture-MS), LIN54 (Affinity Capture-MS)

ESM2 similar proteins: A0AUQ6, A2BE76, O14645, O18973, O35427, O35473, O55003, O88447, O88597, P50503, Q05B58, Q12983, Q13901, Q14457, Q14AM7, Q14CZ0, Q28HY5, Q32KN2, Q32PE4, Q4A1L3, Q4A1L4, Q4A1L5, Q4R3K5, Q4R8N2, Q4RLT3, Q52LA3, Q5JSJ4, Q5NVP8, Q5R878, Q5RBU4, Q5TKA1, Q5ZHS3, Q5ZJQ3, Q68FJ8, Q6DKA1, Q6GMH0, Q6GP52, Q6PAX8, Q6X4M3, Q7TSU0

Diamond homologs: P30630, Q4R8N2, Q5RHQ8, Q5TKA1, Q6A331, Q6A333, Q8C735, Q6A332

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
CDK3	up-regulates	LIN9	phosphorylation
CyclinE1/CDK3	“up-regulates activity”	LIN9	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 73 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
G0 and Early G1	11	80.5×	1e-16
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	8	80.1×	3e-12
Transcription of E2F targets under negative control by DREAM complex	8	72.5×	6e-12
Polo-like kinase mediated events	6	63.4×	2e-08
Cyclin E associated events during G1/S transition	10	47.6×	1e-12
G1/S-Specific Transcription	8	47.6×	3e-10
Cyclin A:Cdk2-associated events at S phase entry	10	44.3×	2e-12
G1/S Transition	6	23.3×	1e-05

GO biological processes:

GO term	Partners	Fold	FDR
G1/S transition of mitotic cell cycle	6	17.2×	2e-04
chromatin remodeling	8	8.3×	5e-04
transcription by RNA polymerase II	8	8.1×	5e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2294 predictions. Top by Δscore:

Variant	Effect	Δscore
1:226233092:TTAC:T	donor_loss	1.0000
1:226233093:TA:T	donor_loss	1.0000
1:226233094:ACCTG:A	donor_loss	1.0000
1:226233095:CCT:C	donor_loss	1.0000
1:226233189:AGACA:A	acceptor_gain	1.0000
1:226233190:GACA:G	acceptor_gain	1.0000
1:226233191:ACA:A	acceptor_gain	1.0000
1:226233192:CA:C	acceptor_gain	1.0000
1:226233192:CAC:C	acceptor_gain	1.0000
1:226233193:ACTAA:A	acceptor_loss	1.0000
1:226233194:C:CC	acceptor_gain	1.0000
1:226234555:T:TA	donor_gain	1.0000
1:226238966:CTTA:C	donor_loss	1.0000
1:226238967:TTA:T	donor_loss	1.0000
1:226238968:TAC:T	donor_loss	1.0000
1:226238969:A:AC	donor_gain	1.0000
1:226238969:AC:A	donor_gain	1.0000
1:226238969:ACCT:A	donor_gain	1.0000
1:226238969:ACCTC:A	donor_loss	1.0000
1:226238970:C:CT	donor_gain	1.0000
1:226238970:CC:C	donor_gain	1.0000
1:226238970:CCT:C	donor_gain	1.0000
1:226238970:CCTC:C	donor_gain	1.0000
1:226238970:CCTCA:C	donor_gain	1.0000
1:226239092:GATTT:G	acceptor_gain	1.0000
1:226239093:ATTT:A	acceptor_gain	1.0000
1:226239094:TTT:T	acceptor_gain	1.0000
1:226239095:TT:T	acceptor_gain	1.0000
1:226239096:TCTGA:T	acceptor_loss	1.0000
1:226239097:C:CC	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000015635 (1:226242792 C>T), RS1000063352 (1:226272721 C>T), RS1000110835 (1:226302913 C>T), RS1000149119 (1:226281776 C>T), RS1000201485 (1:226306004 T>C), RS1000217648 (1:226255064 A>C), RS1000244189 (1:226281574 G>C), RS1000307871 (1:226306248 C>T), RS1000392661 (1:226293828 T>A), RS1000407826 (1:226268111 T>C), RS1000429070 (1:226255289 T>C), RS1000490239 (1:226300181 G>A,C,T), RS1000516214 (1:226305027 G>A), RS1000544749 (1:226261140 A>T), RS1000545526 (1:226256616 T>C)

Disease associations

OMIM: gene MIM:609375 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST009257_10	Caudate nucleus volume	2.000000e-06
GCST010105_147	Nicotine dependence symptom count	6.000000e-06
GCST010816_6	Gut microbiota beta diversity (weighted UniFrac distance)	8.000000e-06
GCST012489_97	Heel bone mineral density x serum urate levels interaction	9.000000e-09
GCST90002390_340	Mean corpuscular hemoglobin	3.000000e-11
GCST90002395_508	Mean platelet volume	5.000000e-12

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004830	caudate nucleus volume
EFO:0009262	nicotine dependence symptom count
EFO:0007874	gut microbiome measurement
EFO:0004531	urate measurement
EFO:0009270	heel bone mineral density
EFO:0004527	mean corpuscular hemoglobin

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	4
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	decreases expression	1
bisphenol A	increases methylation	1
arsenite	decreases reaction, affects binding	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
aflatoxin B2	decreases methylation	1
coumarin	increases phosphorylation	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
2-palmitoylglycerol	increases expression	1
(+)-JQ1 compound	decreases expression	1
Sunitinib	decreases expression	1
Ethanol	decreases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Caffeine	affects phosphorylation	1
Calcitriol	decreases expression, affects cotreatment	1
Cisplatin	increases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Lead	affects expression	1
Lucanthone	decreases expression	1
Testosterone	decreases expression, affects cotreatment	1
Tetrachlorodibenzodioxin	affects expression	1
Thimerosal	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.